AB0901 SUSTAINED REMISSION OR SUSTAINED LOW DISEASE ACTIVITY FOR AT LEAST ONE YEAR IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: ACHIEVABLE OBJECTIVES IN DAILY PRACTICE?
Authors: M. V. Martire, M. Benegas, D. Vila, H. Maldonado Ficco, A. Marcé, M. J. Gamba, J. Morbiducci, M. Cosatti, G. P. Pendon, J. Flores Trejo, L. Ferreyra, L. Casalla, C. A. Isnardi, G. Betancur, D. A. Pereira, E. R. Serrano, M. S. Gálvez Elkin, C. Airoldi
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Different treatment guidelines recommend achieving low activity or remission status in patients with axial spondyloarthritis (axSpA). However, it is still unknown whether this is feasible in clinical practice and the factors related to achieving this state in a sustained manner. <h3>Objectives:</h3> Determine the frequency of sustained remission (SR) or sustained low disease activity (LDAS) for at least one year in patients with AxSpA, and to analyze the associated factors. <h3>Methods:</h3> Multicenter, observational, analytical, retrospective cohort study.Patients with a diagnosis of AxSpA, who meet the ASAS 2009 criteria, in follow-up for at least one year in rheumatology services were included. A review of medical records was carried out. SR was demonstrated if: inactive disease (ASDAS-PCR &lt;1.3) and/or BASDAI &lt; 2 and a normal CRP, and sustained low disease activity if: LDA (ASDAS-PCR ≥1.3 and &lt; 2. 1) and/or BASDAI &lt; 4 and a normal CRP, for at least one year with at least two consecutive visits separated by at least 3 months. Categorical variables were compared using the Chi2 test and continuous variables using Student test or Mann Whitney test. A multiple logistic regression was performed to evaluate the associated factors RS/LDAS. <h3>Results:</h3> 122 patients were included, of which 54% were men, with an average age of 46.45 (SD 15), level of education (measured in years) 14 (IQR 5), time of disease evolution 56 (IQR 96) months and diagnostic delay 24 (IQR 94) months. 96% of patients were under bDMARD treatment. 45% (n=55) achieved SR, 31% (n=38) LDA and 24% (n=29) never achieved any of these states in a sustained manner. Of the 93 patients who achieved RS/LDAS, only 26 (28%) optimized treatment, this strategy being more common in patients with SR (41%) vs LDAS (11%), p:&lt;0.001. The median time in remission was 24 months (IQR 30).SR/LDAS status is maintained in 90% of patients. Table 1 shows the general characteristics of the included patients and the differences between those patients who achieved RS/LDAS and those who never achieved it. In the logistic regression analysis, the lowest baseline activity is independently associated with achieving RS/LDAS (Table 2). <h3>Conclusion:</h3> In this cohort of Argentine patients with axSpA, SR/LDAS was an achievable goal in almost 3 out of 4 patients. Greater baseline activity is associated with fewer possibilities of achieving these goals. Knowing these characteristics can improve therapeutic decision-making in daily practice. <h3>REFERENCES:</h3> [1] Ramiro S, Nikiphorou E, Sepriano A, <i>et al</i>. <i>Ann Rheum Dis</i> 2023;<b>82</b>:19–34. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>